Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.

Authors :: Mikhailova E
Roumiantseva J
Illarionova O
Lagoyko S
Miakova N
Zerkalenkova E
Zharikova L
Olshanskaya Y
Novichkova G
Maschan M
Henze G
Karachunskiy A
Popov A
Source :: British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. e6-e9. Date of Electronic Publication: 2021 Aug 03.
Publication Year :: 2022

Subjects :: Antibodies, Bispecific administration & dosage
Antibodies, Bispecific adverse effects
Antibodies, Bispecific therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Child
Child, Preschool
Humans
Molecular Targeted Therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy
Treatment Outcome
Antigens, CD19 metabolism
Clonal Evolution
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma etiology
Precursor Cells, B-Lymphoid metabolism
Precursor Cells, B-Lymphoid pathology

Full Text Access

Tools